CA Patent

CA2486539A1 — C-aryl glucoside sglt2 inhibitors and method

Assigned to AstraZeneca AB · Expires 2003-12-04 · 22y expired

What this patent protects

An SGLT2 inhibiting compound is provided having the formula~Chemical structure~ A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therape…

USPTO Abstract

An SGLT2 inhibiting compound is provided having the formula~Chemical structure~ A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

Drugs covered by this patent

Patent Metadata

Patent number
CA2486539A1
Jurisdiction
CA
Classification
—
Expires
2003-12-04
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.